Novan, Inc. (NOVN)

5.46
0.01 0.18
NASDAQ
Prev Close 5.45
Open 5.68
Day Low/High 5.30 / 6.05
52 Wk Low/High 3.52 / 30.90
Volume 310.18K
Exchange NASDAQ
Shares Outstanding 15.97B
Market Cap 86.08M
Div & Yield N.A. (N.A)

Latest News

Novan Reports Positive Topline Results With SB208 In Phase 2 Trial

Novan Reports Positive Topline Results With SB208 In Phase 2 Trial

Clinical Evidence of Antifungal Activity Supports Antimicrobial Breadth of Nitric Oxide Platform

Novan Welcomes Key Opinion Leaders To New Advisory Council

Novan Welcomes Key Opinion Leaders To New Advisory Council

Dr. Lawrence Eichenfield to Chair Expert Group Focused on Expanding the Breadth of Nitric Oxide Therapies in Dermatology

Novan Reports Fourth Quarter And Full Year 2016 Financial Results

Novan Reports Fourth Quarter And Full Year 2016 Financial Results

Company Provides Updates on Upcoming Milestones Across the Development Platform

Dr. Nicholas Medendorp, Jr. Named CEO Of PhotonMD, Inc.

Dr. Nicholas Medendorp, Jr. Named CEO Of PhotonMD, Inc.

Medical Device Business is Second Portfolio Company of KNOW Bio, LLC

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Novan Provides Update On SB204 Development Program

Novan Provides Update On SB204 Development Program

Company to Host Conference Call and Webcast to Provide Additional Results of Phase 3 Clinical Trials

Novan's Phase 2 Results With SB206 To Be Presented At 2017 AAD Annual Meeting

Novan's Phase 2 Results With SB206 To Be Presented At 2017 AAD Annual Meeting

Abstract Accepted for Late-breaking Research Presentation by Dr. Stephen Tyring

Novan Announces Presentation Of Anti-Viral Data At International Papillomavirus Conference

Novan Announces Presentation Of Anti-Viral Data At International Papillomavirus Conference

Preclinical Data Showed Significant Inhibition of High-Risk HPV-18 and Reduction of E6 Viral Protein

INVESTOR ALERT: Investigation Of Novan Announced By Holzer & Holzer

INVESTOR ALERT: Investigation Of Novan Announced By Holzer & Holzer

Holzer & Holzer, LLC is investigating whether certain statements issued by Novan Inc.

Anne Whitaker Named CEO Of KNOW Bio Respiratory Company

Anne Whitaker Named CEO Of KNOW Bio Respiratory Company

Targets Cystic Fibrosis using Novel Nitric Oxide Technology

Novan is Now Oversold (NOVN)

Novan is Now Oversold (NOVN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

What's Next for Novan After Its IPO?

What's Next for Novan After Its IPO?

The pharma company is only getting started, says CEO Nate Stasko.

Novan Only Piercing the Skin of Its Potential Says CEO

Novan Only Piercing the Skin of Its Potential Says CEO

With a pair of Phase III trials coming up for its dermatological drug, Novan CEO Nate Stasko says the company is merely piercing the skin of its long-term potential.